Yes, amitriptyline is used off-label for interstitial cystitis/bladder pain syndrome in Australia
Amitriptyline is not specifically approved by regulatory authorities (including the TGA in Australia) for treating interstitial cystitis/bladder pain syndrome (IC/BPS), making its use for this indication off-label. However, this off-label use is well-supported by international clinical guidelines and represents standard practice globally, including in Australia.
Guideline Support for Off-Label Use
The most recent 2022 American Urological Association (AUA) guidelines explicitly state that "none of these treatments are indicated specifically for IC/BPS" when discussing pharmacological options, including amitriptyline 1. Despite this lack of formal indication, amitriptyline receives a Grade B evidence strength recommendation as a second-line oral medication for IC/BPS 1.
The 2017 RCOG Green-top Guideline similarly recommends oral amitriptyline as a second-line treatment when first-line conservative treatments have failed 2. The 2011 AUA guideline grouped amitriptyline with other second-line oral medications, noting these are "options" with Grade B or C evidence 3.
Evidence for Efficacy
Amitriptyline has demonstrated superiority to placebo in improving IC/BPS symptoms across multiple randomized controlled trials:
- Systematic review data from two RCTs (281 patients total) showed trends in improvement for urinary urgency, frequency, and pain scores with doses titrated from 10-100 mg over 4 months 2
- A prospective RCT of 50 patients found statistically significant improvements in symptom scores (26.9 to 18.5 vs. 27.6 to 24.1 for placebo, p=0.005) and pain/urgency intensity (p<0.001) 4
- Long-term data from 94 patients showed a 64% response rate with mean follow-up of 19 months 5
The recommended dosing regimen is to start at 10 mg daily and gradually titrate to 75-100 mg if tolerated 1. Evidence suggests patients who achieve at least 50 mg daily have significantly better outcomes (66% response) compared to placebo (47%, p=0.01) 6.
Important Caveats
Adverse effects are common and can substantially compromise quality of life, though they are not life-threatening 1. The most frequent side effects include:
- Dry mouth (79% of patients) 4
- Sedation and drowsiness
- Weight gain (59% of patients) 5
- Constipation
- Blurred vision 2
The dropout rate due to side effects can be as high as 31% in clinical trials 5. The FDA drug label confirms amitriptyline is only approved for depression, not for IC/BPS or any bladder condition 7.
Clinical Context in Australia
While Australian-specific prescribing data is not provided in the evidence, the UK real-world data shows amitriptyline is the most prevalent medication used for IC/BPS, both alone and in combination 8. In a US Veterans Health Administration cohort, 67% of IC/BPS patients were prescribed an AUA-recommended medication, though amitriptyline prescription rates did not significantly increase after diagnosis (unlike pentosan polysulfate and hydroxyzine) 9.
The off-label use is justified by the chronic pain mechanism of action - amitriptyline's benefits appear independent of antidepressant effects and may take several weeks to manifest 2. The drug works through multiple mechanisms including inhibition of serotonin/noradrenergic reuptake and blockade of muscarinic, adrenergic, and histamine receptors 1.
Treatment Algorithm Position
Amitriptyline should be positioned as:
- After failure of first-line conservative measures (dietary modification, stress management, analgesia, physical therapy) 2
- Before intravesical treatments (lidocaine, hyaluronic acid, botulinum toxin) 2
- As part of multimodal therapy - pain management alone is insufficient; bladder symptoms must also be addressed 1
- With consideration for referral to multidisciplinary pain teams if symptoms remain refractory 2